The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Combining BCL-2 and MCL-1 inhibitors in AML
Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses the latest research from his institute in the area of targeting apoptosis for the treatment of acute myeloid leukemia (AML). Dr Wei highlights the combinantion of BCL-2 and MCL-1 inhibitors, which have shown potent activity in pre-clinical models and are now moving into trials. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
